Antisense modulation of novel anti-apoptotic bcl-2-related proteins
AssigneeIsis Pharmaceuticals, Inc.
InventorsElizabeth J. Ackermann, C. Frank Bennett, Nicholas M. Dean, Eric G. Marcusson
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for modulating the expression of novel anti-apoptotic bcl-2-related proteins. Antisense oligonucleotides targeted to nucleic acids encoding the human novel anti-apoptotic bcl-2-related proteins A1 and mcl-1 are preferred. Methods of using these compounds for modulation of novel anti-apoptotic bcl-2-related protein expression and for treatment of diseases associated with expression of novel anti-apoptotic bcl-2-related proteins are also provided. Also provided are methods of using these compounds for promoting apoptosis and for treatment of diseases for which promotion of apoptosis is desired.
Claims40
An antisense compound 8 to 30 nucleobases in length targeted to either SEQ ID NO:
- 1 or SEQ ID NO:
- 18, nucleic acid molecules encoding novel anti-apoptotic bcl-2-related proteins, wherein said antisense compound inhibits the expression of said novel anti-apoptotic bcl-2-related proteins.
An antisense compound up to 30 nucleobases in length targeted to a nucleic acid encoding human A1 wherein the antisense compound comprises at least 8 nucleobases of SEQ ID NO:
- 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, and inhibits expression of said human A1.
An antisense compound up to 30 nucleobases in length targeted to a nucleic acid encoding human mcl-1 wherein the antisense compound comprises at least 8 nucleobases of SEQ ID NO:
- 22, 23, 31, 35, or 36, and inhibits expression of said human mcl-1.
Dependencies are inferred from the claim text.